| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From Pintex Pharmaceuticals Incorporated,* Watertown, Massachusetts; the Department of Medicine, Division of Hematology/Oncology, Cancer Biology Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and the Institute of Pathology, University of Basel, Basel, Switzerland
Phosphorylation of proteins on serine or threonine residues preceding proline (pSer/Thr-Pro) is a major regulatory mechanism in cell proliferation and transformation. Interestingly, the pSer/Thr-Pro motifs in proteins exist in two distinct cis and trans conformations, whose conversion rate is normally reduced on phosphorylation, but is catalyzed specifically by the prolyl isomerase Pin1. Pin1 can catalytically induce conformational changes in proteins after phosphorylation, thereby having profound effects on catalytic activity, dephosphorylation, protein-protein interactions, subcellular location, and/or turnover of certain phosphorylated proteins. Recently, it has been shown that Pin1 is overexpressed in human breast cancer cell lines and cancer tissues and plays a critical role in the transformation of mammary epithelial cells by activating multiple oncogenic pathways. Furthermore, Pin1 expression is an excellent independent prognostic marker in prostate cancer. However, little is known about Pin1 expression in other human normal and cancerous tissues. In the present study, we quantified Pin1 expression in 2041 human tumor samples and 609 normal tissue samples as well as normal and transformed human cell lines. We found that Pin1 was usually expressed at very low levels in most normal tissues and its expression was normally associated with cell proliferation, with high Pin1 levels being found only in a few cell types. However, Pin1 was strikingly overexpressed in many different human cancers. Most tumors (38 of 60 tumor types) have Pin1 overexpression in more than 10% of the cases, as compared with the corresponding normal controls, which included prostate, lung, ovary, cervical, brain tumors, and melanoma. Consistent with these findings, Pin1 expression in human cancer cell lines was also higher than that in the normal cell lines examined. These results indicate that Pin1 overexpression is a prevalent and specific event in human cancers. Given previous findings that Pin1 expression is an excellent prognostic marker in prostate cancer and that inhibition of Pin1 can suppress transformed phenotypes and inhibit tumor cell growth, these findings may have important implications for the pathogenesis, diagnosis, and treatment of human cancers.
This article has been cited by other articles:
 |
|
 |
|
  A. Tannapfel, K. John, N. Mise, A. Schmidt, S. Buhlmann, S. M. Ibrahim, and B. M. Putzer Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73 Carcinogenesis, January 1, 2008; 29(1): 211 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kesavapany, V. Patel, Y.-L. Zheng, T. K. Pareek, M. Bjelogrlic, W. Albers, N. Amin, H. Jaffe, J. S. Gutkind, M. J. Strong, et al. Inhibition of Pin1 Reduces Glutamate-induced Perikaryal Accumulation of Phosphorylated Neurofilament-H in Neurons Mol. Biol. Cell, September 1, 2007; 18(9): 3645 - 3655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Perez de Castro, G. de Carcer, and M. Malumbres A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy Carcinogenesis, May 1, 2007; 28(5): 899 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Gavini, S. Tungtur, and L. Pulakat Peptidyl-Prolyl cis/trans Isomerase-Independent Functional NifH Mutant of Azotobacter vinelandii. J. Bacteriol., August 1, 2006; 188(16): 6020 - 6025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yu, A. J. Mohamed, L. Vargas, A. Berglof, G. Finn, K. P. Lu, and C. I. E. Smith Regulation of Bruton Tyrosine Kinase by the Peptidylprolyl Isomerase Pin1 J. Biol. Chem., June 30, 2006; 281(26): 18201 - 18207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Suizu, A. Ryo, G. Wulf, J. Lim, and K. P. Lu Pin1 Regulates Centrosome Duplication, and Its Overexpression Induces Centrosome Amplification, Chromosome Instability, and Oncogenesis Mol. Cell. Biol., February 15, 2006; 26(4): 1463 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-Y. Chen, G. Wulf, X. Z. Zhou, M. A. Rubin, K. P. Lu, and S. P. Balk Activation of {beta}-Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor-{beta}-Catenin Interaction Mol. Cell. Biol., February 1, 2006; 26(3): 929 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Yeh, B. O. Lew, and A. R. Means The Loss of PIN1 Deregulates Cyclin E and Sensitizes Mouse Embryo Fibroblasts to Genomic Instability J. Biol. Chem., January 6, 2006; 281(1): 241 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ryo, H. Uemura, H. Ishiguro, T. Saitoh, A. Yamaguchi, K. Perrem, Y. Kubota, K. P. Lu, and I. Aoki Stable Suppression of Tumorigenicity by Pin1-Targeted RNA Interference in Prostate Cancer Clin. Cancer Res., October 15, 2005; 11(20): 7523 - 7531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Currier, S. E. Solomon, E. G. Demicco, D. L. F. Chang, M. Farago, H. Ying, I. Dominguez, G. E. Sonenshein, R. D. Cardiff, Z.-X. J. Xiao, et al. Oncogenic Signaling Pathways Activated in DMBA-Induced Mouse Mammary Tumors Toxicol Pathol, October 1, 2005; 33(6): 726 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Hong, M. S. Ryu, and I. K. Lim Phosphorylation of Serine 147 of tis21/BTG2/pc3 by p-Erk1/2 Induces Pin-1 Binding in Cytoplasm and Cell Death J. Biol. Chem., June 3, 2005; 280(22): 21256 - 21263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Edgar, M. Belvin, A. L. Parks, K. Whittaker, M. B. Mahoney, M. Nicoll, C. C. Park, C. G. Winter, F. Chen, K. Lickteig, et al. Synthetic Lethality of Retinoblastoma Mutant Cells in the Drosophila Eye by Mutation of a Novel Peptidyl Prolyl Isomerase Gene Genetics, May 1, 2005; 170(1): 161 - 171. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
